Pancreatitis Clinical Trial
Official title:
Prospective Comparison Between Ultra Early NKF Versus Standard Cannulation Alone in a Group of High and Low Risk of Pep, Submitted to Pep Prophylaxis
Compare the ultra early fistulotomy strategy with standard cannulation methods for accessing the bile duct during endoscopic retrograde cholangiopancreatography (ERCP)
1. Introduction Endoscopic retrograde cholangiopancreatography (ERCP) is an advanced procedure which is widely used in the diagnosis and treatment of a variety of benign and malignant pancreatobiliary disorders1,2,3,4,5. Selective cannulation of the common bile duct (CBD) is the most important and challenging step in a biliary endoscopic retrograde cholangiopancreatography6,7. However, in the first ERCP, even in experienced hands, biliary cannulation may fail in up to 15 % - 35 % of cases when using standard methods alone8. In this subset of patients, additional cannulation techniques are needed to access the CBD in order to continue with the ERCP. Precut is the most common strategy used by experienced endoscopists, when conventional methods have failed7. Needle knife fistulotomy (NKF) and conventional precut are the two most common variants. Recently published guidelines recommend opting for NKF, as evidence suggests a lower risk of adverse events, especially pancreatitis, when used early in the biliary cannulation algorithm7,9. Technically NKF is the creation of an artificial fistula between the most protuberant portion of the papilla, which represents the intraduodenal portion of the CBD and the biliary tract by using a diathermic cutter of the needle type6,10,11,12,13,14,15,16,17,18. Its big advantage over conventional precut is that it avoids the contact of the cutting device with the papillary orifice and therefore avoiding direct thermal injury to the pancreatic duct. Although NKF was originally developed as a rescue technique, to be used after previous failed standard cannulations attempts, it is being increasingly used at an early stage during ERCP. Given its safety and feasibility some authors even advocate, the once unreasonable, primary use without previous standard cannulation attempts10,11,19,20. 2. Financial resources All participants included in this study will perform ERCP, laboratory tests and other complementary diagnostic tests after a duly justified medical prescription. Therefore there are no additional costs or consumption of hospital resources. 3. Ethical considerations In this study, participants will be included after informed consent. Anonymity and confidentiality will be safeguarded by assigning an individual numeric code. It will also be explained the possibility of withdrawing from the study at any time, with the guarantee of the total elimination of data. All researchers involved in the study will adhere to the Rules of Ethical Conduct and Best Practices in order to comply with the precepts of the Declaration of Helsinki, the Convention on Human Rights and Biomedicine, the guidelines of the Council for International Organizations of Medical Sciences and the Guide to Good Clinical Practice. 4. Statistical analysis Qualitative variables will be summarized using absolute and relative frequencies, and quantitative variables will be summarized using the mean and standard deviation or the median and interquartile range, depending on their distribution profiles. The normality of the quantitative variables will be assessed using the histogram distribution. A sample of 334 (167 in each group) patients will provide 80% power to detect a difference of 5% in pancreatitis rates between the two groups based on a chi-square test, assuming a pancreatitis rate of 1% among primary fistulotomy, 6 and a one-tailed alpha of 0.05. Relations between categorical variables will be assessed using a chi-square test and Fisher´s exact test. Differences between two or more groups of independent non-normally distributed quantitative variables will be evaluated using a Kruskal-Wallis test. To explain the risk of pancreatitis, a binomial logistic regression model with multiple predictors will be performed. The null hypothesis will be rejected when the test statistics p-values are less than <0.05. Statistical analysis, sample size calculation and graphics will be performed using Stata software (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, StataCorp LP) 5. Expected results The results of this study will contribute to a better understanding of what is the best algorithm to follow when performing an ERCP. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03609944 -
SpHincterotomy for Acute Recurrent Pancreatitis
|
N/A | |
Not yet recruiting |
NCT04652271 -
International Pancreatic Surgery Outcomes Study - PancreasGroup.Org
|
||
Completed |
NCT01441492 -
Pancreas Resection With and Without Drains
|
N/A | |
Recruiting |
NCT02196935 -
Los Angeles Prospective GI Biliary and EUS Series
|
||
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01545167 -
The North American Pancreatitis Study
|
N/A | |
Completed |
NCT04168801 -
Early Oral Refeeding in Mild Acute Pancreatitis
|
N/A | |
Recruiting |
NCT03334708 -
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
|
||
Completed |
NCT01824186 -
Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy
|
N/A | |
Terminated |
NCT00428025 -
Diclofenac for the Prevention of Post-ERCP Pancreatitis in Higher Risk Patients
|
Phase 4 | |
Completed |
NCT00639314 -
Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy
|
N/A | |
Recruiting |
NCT00160836 -
Biliary Tissue Sampling Using a Cytology Brush or the GIUM Catheter
|
Phase 1 | |
Completed |
NCT00121901 -
Does Glyceryl Nitrate Prevent Post-Endoscopic Retrograde Cholangiopancreaticography (ERCP) Pancreatitis?
|
Phase 3 | |
Completed |
NCT00999232 -
Assess the Effect of Erythromycin on the Rate of Success in Placement of a Self-propelled Feeding Tube
|
Phase 4 | |
Terminated |
NCT00419549 -
Efficacy Study of Glyceryl-Trinitrate Patch and Parecoxib (Valdecoxib) for the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (ERCP)
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05095831 -
EUS Shear Wave for Solid Pancreatic Lesions.
|
||
Completed |
NCT03601325 -
Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
|
||
Withdrawn |
NCT02465138 -
A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis
|
Phase 4 | |
Not yet recruiting |
NCT06133023 -
WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts
|
N/A | |
Recruiting |
NCT02971475 -
ESWL Versus ESWL and Endoscopic Treatment
|
N/A |